Definition

A preparation of T lymphocytes that are genetically engineered to express a fourth-generation chimeric antigen receptor (4SCAR) targeting the two tumor-associated antigens (TAAs) disialoganglioside (GD2) and CD56 (neural cell adhesion molecule 1; NCAM-1), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-GD2/anti-CD56 4SCAR-expressing bispecific T cells are directed to and induce selective toxicity in GD2- and CD56-expressing tumor cells. GD2 is overexpressed on the surface of neuroblastoma cells and by other neuroectoderm-derived neoplasms, while it is minimally expressed on normal cells. CD56 is overexpressed on the surface of various types of cancer cells, including small cell lung cancer (SCLC) and other neuroendocrine tumors (NETs).